刘 腾,段直光

目的：评价地塞米松植入剂（Ozurdex）联合康柏西普（Conbercept）及各单药玻璃体注射治疗视网膜分支静脉阻塞伴黄斑水肿（BRVO-ME）的临床疗效。方法：分析比较两类型患者三组治疗后最佳矫正视力（BCVA）、黄斑中心凹厚度（CFT）、黄斑容积（MV）、视网膜平均厚度（CRT）、注射次数、眼内压（IOP）、并发症。结果：两型三组患者治疗后BCVA、MV和CFT及CRT均优于治疗前；联合组治疗后BCVA、MV和CFT及CRT均优于其他两组；非缺血型患者Conbercept组及Ozurdex组的视力提高及MV的下降程度优于缺血型患者相应组，IOP和CFT及CRT在缺血型与非缺血型患者中差异无统计学意义。结论：Ozurdex联合Conbercept治疗BRVO-ME，短期疗效好，再治疗时间较其它两组长，可以用相对较少的注射次数使患者在在视力和解剖学获益，药效持续时间更久。

视网膜分支静脉阻塞；黄斑水肿；地塞米松植入剂；康柏西普

[1]Sivaprasad S, Amoaku WM, Hykin P, et al. The royal college of ophthalmologists guidelines on retinal vein occlusions: executive summary[J]. Eye (Lond), 2016, 30(4): 642. [2]Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, etal. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA)[J]. Ophthalmologica, 2019;242(3):123-162. [3] Ding Xuefei,Hu Yijun,Yu Honghua et al. Changes of Optical Coherence Tomography Biomarkers in Macular Edema Secondary to Retinal Vein Occlusion After Anti-VEGF and Anti-Inflammatory Therapies.[J] .Drug Des Devel Ther, 2022, 16: 717-725. [4]方丽英,黄宝宇,黄敏丽.Ozurdex与康柏西普治疗视网膜静脉阻塞继发黄斑水肿的疗效对比[J].眼科新进展,2021,41(03):231-235. [5]Li X, Wang N, Liang X, et al. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, shamcontrolled, multicenter study[J]. Graefe's Arch Clin Exp Ophthalmol, 2018, 256(1): 59-69. [6]Gu X, Yu X, Song S, et al. Intravitreal dexamethasone implant versus intravitreal ranibizumab for the treatment of macular edema secondary to retinal vein occlusion in a Chinese population[J]. Ophthalmic Res, 2017, 58(1): 8-14. [7] Chatziralli Irini,Theodossiadis George,Kabanarou Stamatina A et al. Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study.[J].Graefes Arch Clin Exp Ophthalmol, 2017,255: 1899-1905. [8] Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, OZURDEX GENEVA Study Group (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlu- sion[J]. Ophthalmology,2011,117(6):1134– 1146. [9]Iu LP, Zhao P, Yeung IY, et al. Sequential therapy with ranibizumab and dexamethasone intravitreal implant is better than dexamethasone monotherapy for macular oedema due to retinal vein occlusion[J]. Br J Ophthalmol, 2015, 99(2): 210-214. [10]Lee Kyou Ho,Kang Eui Chun,Koh Hyoung Jun,Dexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion.[J] .Korean J Ophthalmol, 2017 Apr;31(2):108-114.

点击下载PDF